Wesbanco Bank Inc. Acquires Shares of 98,000 Bioventus Inc. $BVS

Wesbanco Bank Inc. acquired a new stake in Bioventus Inc. (NASDAQ:BVS) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 98,000 shares of the company’s stock, valued at approximately $895,000. Wesbanco Bank Inc. owned 0.12% of Bioventus at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Caitong International Asset Management Co. Ltd raised its position in Bioventus by 17,156.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares during the last quarter. SG Americas Securities LLC purchased a new position in Bioventus during the 4th quarter worth $80,000. Diversified Trust Co acquired a new position in Bioventus in the first quarter valued at $100,000. Prelude Capital Management LLC acquired a new position in Bioventus in the third quarter valued at $74,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Bioventus in the third quarter valued at about $78,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Stock Performance

Shares of Bioventus stock opened at $9.78 on Monday. Bioventus Inc. has a 52-week low of $5.81 and a 52-week high of $11.25. The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. The company’s 50-day simple moving average is $9.55 and its 200-day simple moving average is $8.75. The firm has a market cap of $816.97 million, a price-to-earnings ratio of 23.85, a price-to-earnings-growth ratio of 1.26 and a beta of 0.67.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.06. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. The firm had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, equities research analysts anticipate that Bioventus Inc. will post 0.77 earnings per share for the current year.

Analyst Ratings Changes

BVS has been the topic of a number of research reports. Craig Hallum raised their price target on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Barrington Research reaffirmed an “outperform” rating and set a $14.00 price objective on shares of Bioventus in a research note on Friday, May 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. CJS Securities started coverage on Bioventus in a research note on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price on the stock. Finally, Cantor Fitzgerald raised Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $14.20.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.